Интенсифицированная неоадъювантная химиотерапия в уплотненном режиме с использованием комбинаций паклитаксела с гемцитабином и доцетаксела с доксорубицином при местно-распространенном раке молочной железы

Разработанный режим химиотерапии (ХТ) паклитакселом и гемцитабином с сокращением интервала между циклами до 2 нед позволяет в 1,5 раза сократить сроки проведения предоперационного лечения и может быть изучен далее в неоадъювантной ХТ операбельного рака молочной железы. Интенсифицированная ХТ в режиме паклитаксел 175 мг/м2 1-й день + гемцитабин 2000 мг/м2 1-й день, доцетаксел 70 мг/м2 1-й день + доксорубицин 60 мг/м2 1-й день + колониестимулирующий фактор каждые 2 нед обладает высокой клинической эффективностью и удовлетворительной переносимостью.

местно-распространенный рак молочной железы, dose-dense химиотерапия, паклитаксел, гемцитабин, доцетаксел, доксорубицин, неоадъювантная химиотерапия

1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 году. Вестн РОНЦ 2010;21(1):57−9.

2. Hortobagyi G.N., Buzdar A.U., Strom E.A. et al. Primary chemotherapy for early and advanced breast cancer. Cancer Lett 1995;90(1):103−9.

3. Haagensen C.D., Stout A.P. Carcinoma of the breast. P. I. Results of treatment. Ann Surg 1942;116(6):801−15.

4. Haagensen C.D., Stout A.P. Carcinoma of the breast. P. II. Criteria of operability. Ann Surg 1943;118:859−870,1032−51.

5. Bonadonna G., Valagussa P., Moliterni P. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332(14):901−6.

6. Портной С.М. Лечение местно-распространенного рака молочной железы. Российская научно-практическая конференция «Современные аспекты диагностики и лечения рака молочной железы». Сибирск онкол журн 2008;2:14−22.

7. Coskun U., Gunel N., Onuk E. et al. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer. Neoplasma 2003;50(3):210−6.

8. Jones R.L, Salter J., A'Hern R. et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemo- therapy for breast cancer. Breast Cancer Res Treat 2010;119(2):315−23.

9. Colleoni M., Viale G., Zahrieh D. et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10(19):6662−8.

10. Rouzier R., Perou C.M., Symmans W.F. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;II(16): 5678−85.

11. Carey L.A., Dees E.C., Sawyer L. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329−34.

12. Liedtke C., Mazouni C., Hess K.R. et al. Response to neoadjuvant therapy and long-term survival in patients with triple- negative breast cancer. J Clin Oncol 2008; 26(8):1275−81.

13. Haagensen C. Diseases of the breast. Philadelphia, Saunders, 1965.

14. Борисов В.И., Сарибекян Э.Л. Нео- адъювантная ХТ рака молочной железы.В кн.: Новое в терапии рака молочной же- лезы. М., 1998. С. 43−7.

15. Тюляндин C.А. Значение предоперационной химиотерапии у больных раком молочной железы. Материалы IV ежегодной Росс онкол конференции, 2009.

16. Colozza M., Gori S., Mosconi A.M. et al. Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long term results. Am J Clin Oncol 1996; 19(1):10−7.

17. Smith I.С., Heys S.D., Hutcheon A.W. et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20(6): 1456−66.

18. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005;10(6):370−81.

19. Skipper H.E., Schabel F.M., Wilcox X. Experimental evaluation of potential anticancer agents. XIII: On the criteria and kinetics associated with «curability» of experimental leukemia. Cancer Chemother Rep 1964;35:1−111.

20. Skipper H.E. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971;28(6):1479−99.

21. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70(1):163−9.

22. Norton L., Simon R., Brereton H.D. et al. Predicting the course of Gompertzian growth. Nature 1976;264(5586):542−55.

23. Hortobagyi G.N., Ames F.C., Buzdar A.U. et al. Management of stage III primary breast cancer with primary chemotherapy surgery, and radiation therapy. Cancer 1988; 62:2507−16.

24. Perloff M., Lesnick G.J., Korzun A. et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: A Cancer and Leukemia Group B Study. J Clin Oncol 1988;6:261−9.

25. Pierce L.J., Lippman M., Ben-Baruch N. et al. The effect of systemic therapy on local- regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:949−60.

26. Low J.A., Berman A.W., Steinberg S.M. et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067−74.

27. Ueno N.T., Buzdar A.U., Singletary S.E. et al. Combined-modality treatment of inflam- matory breast carcinoma: Twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321−9.

28. Clark J., Rosenman J., Cance W. et al. Extending the indications for breast- conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1998;42:345−50.

29. Kuerer H.M., Newman L.A., Smith T.L. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin- based neoadjuvant chemotherapy. J Clin Oncol 1999;17(2):460−9.

30. Cristofanilli M., Buzdar A.U., Snelge N. et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92:1775−82.

31. Favret A.M., Carlson R.W., Goffinet D.R. et al. Locally advanced breast cancer: Is surgery necessary? Breast J 2001;7:131−7.

32. Heys S.D., Hutcheon A.W., Sarkar T.K. et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3 Suppl 2:S69–74.

33. Harris E.E., Schultz D., Bertsch H. et al. Ten year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1200−18.

34. McIntosh S.A., Ogston K.N., Payne S. et al. Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 2003;185(6):525−31.

35. Therasse P., Mauriac L., Welnicka-Jaskiewicz M. el al. Final results of a randomized phase III trial comparing cyclo- phosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21(5):843−50.

36. Espinosa E., Morales S., Borrega P. et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol 2004;54(6):546−52.

37. Ezzat A.A., Ibrahim E.M., Ajarim D.S. et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 2004;90(5):968−74.

38. Gajdos C., Tartter P.I., Estabrook A. et al. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002;80(1):4−11.

39. Lebowitz P.F., Eng-Wong J., Swain S.M. et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 2004;10(20):6764−9.

40. De Matteis A., Nuzzo F., D'Aiuto G. et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 2002; 94(4):895−901.

41. Shen J., Valero V., Buchholz Т.А. et al. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 2004;11(9):854−60. 42. Thomas E., Holmes F.A., Smith T.L. et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women

42. with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004;22:2294−302.

43. Erol K., Baltali E., Altundag K. et al. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer. Onkologie 2005;28(2):81−5.

44. Gradishar W.J., Wedam S.B., Jahanzeb M. et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage Ш breast cancer. Ann Oncol 2005;16(8):1297−304.

45. Tham Y.L., Gomez L.F., Mohsin S. et al. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers, Breast Cancer Res Treat 2005;94(3):279−84.

46. Veyret C., Levy C., Chollet P. et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 2006;107(11):2535−44.

47. Ellis G.K., Green S.J., Russell C.A. et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:537−9.

48. Villman K., Ohd J.F., Lidbrink E. et al.A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer 2007;43:1153−60.

49. Von Minckwitz G., Kümmel S., Vogel P. et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100(8):552−62.

50. Manga G.P., Shahi P.K., Urena M.M. et al. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine in locally advanced or inflammatory breast cancer. Breast Cancer 2009, doi: 10.1007/s12282-009-0136-6.